Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Total World Stock Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard Total World Stock Index Fund ETF trades at $157.18 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 9.1× Repligen Corporation Common Stock's market cap, and Vanguard Total World Stock Index Fund ETF is more actively traded (7,186,242 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Total World Stock Index Fund ETF for 54 Days on average.
| RGEN | VT | |
|---|---|---|
Market Cap | $11.14B | $101.70B |
Volume | 1,259,263 | 7,186,242 |
Sector | Health | Broad Market / Factor |
52-Week High | $194.57 | $162.39 |
52-Week Low | $102.87 | $134.19 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Vanguard Total World Stock ETF (VT) trades at $159.76, showing modest daily gains of 0.16% with neutral technical indicators. The ETF maintains broad global diversification across 9,773 stocks with a low 0.06% expense ratio. Recent news highlights VT's strong five-year performance compared to international-focused peers, though some competitors offer lower fees. Technical analysis shows the ETF trading near pivot point resistance at $160 with support at $159.
VT provides comprehensive global equity exposure but faces fee competition from alternatives like SPDW. The ETF's broad diversification minimizes country-specific risks while capturing global growth. Key risks include expense ratio pressure and emerging market volatility. Analyst sentiment remains positive for long-term investors seeking one-stop global diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
